Yoly
Lv5
900 积分
2021-02-23 加入
-
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
16小时前
待确认
-
Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma
17小时前
待确认
-
PD1/PDL1 clinical trials adapt to a growing landscape of patients resistant to PDx
4个月前
已完结
-
Opportunities and Challenges for a Histology-Agnostic Utilization of Trastuzumab Deruxtecan
4个月前
已完结
-
Analysis of pharma R&D productivity – a new perspective needed
5个月前
已完结
-
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
6个月前
已完结
-
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
10个月前
已完结
-
Rare molecular subtypes of lung cancer
10个月前
已完结
-
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
10个月前
已完结
-
Rare molecular subtypes of lung cancer
1年前
已完结